A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody (LY3300054).
Your participation in this trial could last up to 24 months, depending on your cancer type and how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
-Participants must have a diagnosis of cancer (solid tumor) that has spread to other parts of the body
-Participants must be willing to provide required, newly acquired tumor biopsies (doctor removes a small amount of tissue)
-Participants must not have cancer that has spread to the brain
-Participants must not have an HIV infection or hepatitis B or C
-Participants must not have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor
-Participants must not have an active autoimmune disease or currently require immunosuppression of >10 milligrams of prednisone or equivalent per day
-Participants must not have lung disease or inflammation of the lungs or a history of lung inflammation that required steroids